Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases

Clinical Rheumatology

Volumn 27, Issue 7, 2008, Pages 909-912

  Inoue, Yuzaburo ^a   Shimojo, Naoki ^a   Suzuki, Shuichi ^a   Arima, Takayasu ^a   Tomiita, Minako ^a   Minagawa, Masanori ^a   Kohno, Yoichi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Alendronate; Glucocorticoids; Osteoporosis; Pediatric rheumatic diseases

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; DEOXYPYRIDINOLINE; GLUCOCORTICOID; VITAMIN D;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE DISEASE; BONE DENSITY; BONE TURNOVER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMUR NECK; FLU LIKE SYNDROME; HUMAN; MALE; OSTEOLYSIS; PRIORITY JOURNAL; TREATMENT DURATION; URINE LEVEL;

ALENDRONATE; ANTIRHEUMATIC AGENTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CHILD; FEMALE; GLUCOCORTICOIDS; HUMANS; INFUSIONS, INTRAVENOUS; LONGITUDINAL STUDIES; MALE; OSTEOPOROSIS; PILOT PROJECTS; RHEUMATIC DISEASES;

EID: 45049088334     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-008-0864-6     Document Type: Article

References (25)

1. Cetin A, Celiker R, Dincer F et al (1998) Bone mineral density in children with juvenile chronic arthritis. Clin Rheumatol 17:551-553
2. Falcini F, Trapani S, Civinini R et al (1996) The primary role of steroids on the osteoporosis in juvenile rheumatoid patients evaluated by dual energy X-ray absorptiometry. J Endocrinol Invest 19:165-169
3. Trapani S, Civinini R, Ermini M et al (1998) Osteoporosis in juvenile systemic lupus erythematosus: A longitudinal study on the effect of steroids on bone mineral density. Rheumatol Int 18:45-49
4. Siomou E, Challa A, Tzoufi M et al (2003) Biochemical markers of bone metabolism in infants and children under intravenous corticosteroid therapy. Calcif Tissue Int 73:319-325
5. Rabinovich CE (2004) Osteoporosis: A pediatric perspective. Arthritis Rheum 50:1023-1025
6. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 44:1496-1503
7. Bone and Tooth Society of Great Britain, National Osteoporosis Society, Royal College of Physicians (2002) Glucocorticoid-induced osteoporosis: a concise guide to prevention and treatment. Available at http://www.rcplondon.ac.uk/pubs/books/glucocorticoid/
8. Nawata H, Soen S, Takayanagi R et al (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23:105-109
9. Rodan GA, Fleisch HA (1996) Bisphosphonates: Mechanisms of action. J Clin Invest 97:2692-2696
10. Bianchi ML, Cimaz R, Bardare M et al (2000) Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: A prospective multicenter study. Arthritis Rheum 43:1960-1966
11. Noguera A, Ros JB, Pavia C et al (2003) Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J Pediatr Endocrinol Metab 16:529-536
12. Papaioannou A, Ioannidis G, Adachi JD et al (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:808-813
13. Segal E, Tamir A, Ish-Shalom S (2003) Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 5:859-862
14. Passeri M, Baroni MC, Pedrazzoni M et al (1991) Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 15:237-247
15. Thiebaud D, Burckhardt P, Kriegbaum H et al (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298-307
16. Thiebaud D, Burckhardt P, Melchior J et al (1994) Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 4:76-83
17. Takahashi Y, Minamitani K, Kobayashi Y et al (1996) Spinal and femoral bone mass accumulation during normal adolescence: Comparison with female patients with sexual precocity and with hypogonadism. J Clin Endocrinol Metab 81:1248-1253
18. DiMeglio LA, Ford L, McClintock C et al (2004) Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 35:1038-1045
19. Simon JA, Lewiecki EM, Smith ME et al (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study. Clin Ther 24:1871-1886
20. Emkey R, Koltun W, Beusterien K et al (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: The Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895-1903
21. Srivastava T, Alon US (2003) The role of bisphosphonates in diseases of childhood. Eur J Pediatr 162:735-751
22. Brumsen C, Hamdy NA, Papapoulos SE (1997) Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 76:266-283
23. van Persijn van Meerten EL, Kroon HM, Papapoulos SE (1992) Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology 184:249-254
24. Illidge TM, Hussey M, Godden CW (1996) Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol (R Coll Radiol) 8:257-258
25. Munns CF, Rauch F, Ward L et al (2004) Maternal and fetal outcome after long-term pamidronate treatment before conception: A report of two cases. J Bone Miner Res 19:1742-1745